IceCure Medical Ltd.
ICCM
Positions held
Your positionsICCM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $5.24M | Enterprise value | -$8.07M | Trailing P/E | — | Forward P/E | -0.34 |
| PEG | — | Price / book | 0.33 | Beta | 0.43 | Dividend yield | 0.00% |
| Revenue growth | 72.8% | Earnings growth | — | Gross margin | 36.1% | Operating margin | -4.9% |
| Profit margin | 0.0% | ROE | -2.3% | ROA | -73.9% | Debt / equity | 0.01 |
| Current ratio | 2.88 | Free cash flow | -$9.54M | Analyst recommendation | none | Mean target | $22.67 |
| 52w high | $30.30 | 52w low | $1.05 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.9M | $0.9M | $1.3M | $0.8M | $0.5M | — |
| Op margin | -487.8% | -466.2% | -329.6% | -451.3% | -644.8% | — |
| Net income | -$4.5M | -$4.3M | -$4.2M | -$3.9M | -$3.4M | — |
| Gross margin | 27.9% | 32.4% | 46.9% | 32.6% | 25.0% | — |
| Gross profit | $0.3M | $0.3M | $0.6M | $0.3M | $0.1M | — |
| Operating income | -$4.4M | -$4.2M | -$4.2M | -$3.8M | -$3.4M | — |
- Revenue -0% vs prior quarter ($0.9M vs $0.9M).
- Gross margin 27.9% (was 32.4% prior quarter).
- Operating margin compressed to -487.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $3.4M | $3.3M | $3.2M | $3.1M |
| Op margin | -446.7% | -476.9% | -482.4% | -542.6% |
| Net income | -$15.1M | -$15.3M | -$14.7M | -$17.0M |
| Gross margin | 36.3% | 44.1% | 40.3% | 46.8% |
| Gross profit | $1.2M | $1.5M | $1.3M | $1.4M |
| Operating income | -$15.1M | -$15.7M | -$15.6M | -$16.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-11 · IceCure Secures China NMPA Approval for ProSense Cryoablation System
2026-09-10 · IceCure Medical Receives Regulatory Approval to Market ProSense® in China
2026-08-24 · IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
2026-08-20 · West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
2026-08-20 · Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as US ...
2026-08-19 · IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript
2026-08-12 · IceCure Medical Ltd Q2 2026 Earnings Call Summary
2026-08-12 · IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
2026-08-11 · Earnings To Watch: Icecure Medical Ltd (ICCM) Q2 2026 -- GF Value Sees 452% Upside
2026-08-06 · Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns